🌖A new video-devlog for Moons in Crystal is up!🔮
🎨"A Visual Update"🧱
www.youtube.com/watch?v=pCvX...
#MoonsInCrystal #Metroidvania #IndieGame #IndieDev #GameDev #Devlog
🎨"A Visual Update"🧱
www.youtube.com/watch?v=pCvX...
#MoonsInCrystal #Metroidvania #IndieGame #IndieDev #GameDev #Devlog
Moons in Crystal--Video Devlog 6.5--"A Visual Update"
YouTube video by Ian Eborn
www.youtube.com
January 14, 2026 at 11:14 AM
🌖A new video-devlog for Moons in Crystal is up!🔮
🎨"A Visual Update"🧱
www.youtube.com/watch?v=pCvX...
#MoonsInCrystal #Metroidvania #IndieGame #IndieDev #GameDev #Devlog
🎨"A Visual Update"🧱
www.youtube.com/watch?v=pCvX...
#MoonsInCrystal #Metroidvania #IndieGame #IndieDev #GameDev #Devlog
My book: “Under the Shadows of Words”
Here’s the link: online.fliphtml5.com/jwxyt/pcvx/
In case you're interested in reading it. You can read for free
@georgeyuhasz-7.bsky.social @norbaikin.bsky.social @mattstarrfineart.bsky.social @cathaguamia.bsky.social
Here’s the link: online.fliphtml5.com/jwxyt/pcvx/
In case you're interested in reading it. You can read for free
@georgeyuhasz-7.bsky.social @norbaikin.bsky.social @mattstarrfineart.bsky.social @cathaguamia.bsky.social
February 28, 2026 at 4:42 PM
My book: “Under the Shadows of Words”
Here’s the link: online.fliphtml5.com/jwxyt/pcvx/
In case you're interested in reading it. You can read for free
@georgeyuhasz-7.bsky.social @norbaikin.bsky.social @mattstarrfineart.bsky.social @cathaguamia.bsky.social
Here’s the link: online.fliphtml5.com/jwxyt/pcvx/
In case you're interested in reading it. You can read for free
@georgeyuhasz-7.bsky.social @norbaikin.bsky.social @mattstarrfineart.bsky.social @cathaguamia.bsky.social
Konnichiwa~ Minna~ $PCVX is getting love 💖 Sentiment score is way up Otsukaresama~!
October 5, 2026 at 2:18 PM
Konnichiwa~ Minna~ $PCVX is getting love 💖 Sentiment score is way up Otsukaresama~!
🚨 $PCVX
Cowan Elvia, a Officer, filed a notice of intent to sell 19,000 shares of common stock, valued at approximately $1,648,060.00, on 10/05/2026.
Cowan Elvia, a Officer, filed a notice of intent to sell 19,000 shares of common stock, valued at approximately $1,648,060.00, on 10/05/2026.
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
October 5, 2026 at 8:38 PM
🚨 $PCVX
Cowan Elvia, a Officer, filed a notice of intent to sell 19,000 shares of common stock, valued at approximately $1,648,060.00, on 10/05/2026.
Cowan Elvia, a Officer, filed a notice of intent to sell 19,000 shares of common stock, valued at approximately $1,648,060.00, on 10/05/2026.
📰 News Snapshot (24h)
⚪ $PCVX · GlobeNewswire: Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
⚪ $PTC… #PCVX #PTC #investing #stocks #StockMarket
⚪ $PCVX · GlobeNewswire: Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
⚪ $PTC… #PCVX #PTC #investing #stocks #StockMarket
October 4, 2026 at 9:29 PM
📰 News Snapshot (24h)
⚪ $PCVX · GlobeNewswire: Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
⚪ $PTC… #PCVX #PTC #investing #stocks #StockMarket
⚪ $PCVX · GlobeNewswire: Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
⚪ $PTC… #PCVX #PTC #investing #stocks #StockMarket
$PCVX — Vaxcyte's PCVX stock surges on positive Phase 3 pneumococcal vaccine data, overshadowing consistent net losses.
Positive topline data from Phase 3 trial for VAX-31 met primary endpoints. Consistent net losses reported.
https://market-scanner.net/tickers/PCVX.US
#ai #trading
Positive topline data from Phase 3 trial for VAX-31 met primary endpoints. Consistent net losses reported.
https://market-scanner.net/tickers/PCVX.US
#ai #trading
PCVX.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
October 5, 2026 at 2:18 PM
$PCVX — Vaxcyte's PCVX stock surges on positive Phase 3 pneumococcal vaccine data, overshadowing consistent net losses.
Positive topline data from Phase 3 trial for VAX-31 met primary endpoints. Consistent net losses reported.
https://market-scanner.net/tickers/PCVX.US
#ai #trading
Positive topline data from Phase 3 trial for VAX-31 met primary endpoints. Consistent net losses reported.
https://market-scanner.net/tickers/PCVX.US
#ai #trading
🚨 $PCVX
On October 5, 2026, Vaxcyte, Inc. issued a press release announcing positive topline data from its Phase 3 OPUS-1 pivotal adult trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine candidate designed to prevent inva...
On October 5, 2026, Vaxcyte, Inc. issued a press release announcing positive topline data from its Phase 3 OPUS-1 pivotal adult trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine candidate designed to prevent inva...
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
October 5, 2026 at 12:01 PM
🚨 $PCVX
On October 5, 2026, Vaxcyte, Inc. issued a press release announcing positive topline data from its Phase 3 OPUS-1 pivotal adult trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine candidate designed to prevent inva...
On October 5, 2026, Vaxcyte, Inc. issued a press release announcing positive topline data from its Phase 3 OPUS-1 pivotal adult trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine candidate designed to prevent inva...
Breaking News: ( NASDAQ: #PCVX ) Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate
October 5, 2026 at 2:01 PM
5 stocks. 4 markets. Up to +32.86%. 📈
XP +32.86%
PCVX +31.56%
INTT +29.99%
ITUB +22.32%
BB +11.84%
Find more opportunities with Swing Pilot.
swingpilot.app
Historical examples. Not financial advice.
XP +32.86%
PCVX +31.56%
INTT +29.99%
ITUB +22.32%
BB +11.84%
Find more opportunities with Swing Pilot.
swingpilot.app
Historical examples. Not financial advice.
October 5, 2026 at 10:57 PM
5 stocks. 4 markets. Up to +32.86%. 📈
XP +32.86%
PCVX +31.56%
INTT +29.99%
ITUB +22.32%
BB +11.84%
Find more opportunities with Swing Pilot.
swingpilot.app
Historical examples. Not financial advice.
XP +32.86%
PCVX +31.56%
INTT +29.99%
ITUB +22.32%
BB +11.84%
Find more opportunities with Swing Pilot.
swingpilot.app
Historical examples. Not financial advice.
#PCVX Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
https://www.stocktitan.net/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offerings-of-6pvuitynq6s0.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offerings-of-6pvuitynq6s0.html?utm_source=stocktitan-bluesky&utm_medium=social
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 5, 2026 at 8:28 PM
#PCVX Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
https://www.stocktitan.net/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offerings-of-6pvuitynq6s0.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offerings-of-6pvuitynq6s0.html?utm_source=stocktitan-bluesky&utm_medium=social
#PCVX Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
https://www.stocktitan.net/news/PCVX/vaxcyte-announces-pricing-of-concurrent-public-offerings-of-common-64iikdoatxt3.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PCVX/vaxcyte-announces-pricing-of-concurrent-public-offerings-of-common-64iikdoatxt3.html?utm_source=stocktitan-bluesky&utm_medium=social
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 7, 2026 at 2:48 AM
#PCVX Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
https://www.stocktitan.net/news/PCVX/vaxcyte-announces-pricing-of-concurrent-public-offerings-of-common-64iikdoatxt3.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PCVX/vaxcyte-announces-pricing-of-concurrent-public-offerings-of-common-64iikdoatxt3.html?utm_source=stocktitan-bluesky&utm_medium=social
Shares of San Carlos-based Vaxcyte (Nasdaq: PCVX) surged nearly 30% Monday after late-stage trial results signaled its lead vaccine candidate could steal significant share from Pfizer and Merck.
Daily Digest: Fleet Week returns to S.F., GGU scours city for new digs
Shares of San Carlos-based Vaxcyte (Nasdaq: PCVX) surged nearly 30% Monday after late-stage trial results signaled its lead vaccine candidate could steal significant share from Pfizer and Merck.
bit.ly
October 5, 2026 at 8:15 PM
Shares of San Carlos-based Vaxcyte (Nasdaq: PCVX) surged nearly 30% Monday after late-stage trial results signaled its lead vaccine candidate could steal significant share from Pfizer and Merck.
▲ $PCVX Vaxcyte: Positive Phase 3 OPUS-1 topline data for VAX-31, a 31-valent pneumococcal vaccine, represents a major derisking event; expect significant upside as data details emerge [BULLISH]
October 5, 2026 at 2:30 PM
▲ $PCVX Vaxcyte: Positive Phase 3 OPUS-1 topline data for VAX-31, a 31-valent pneumococcal vaccine, represents a major derisking event; expect significant upside as data details emerge [BULLISH]
🚨 $PCVX
Wassil Jim, a Officer, filed a notice of intent to sell 2,250 shares of common stock, valued at approximately $127,642.50, on 10/01/2026.
Wassil Jim, a Officer, filed a notice of intent to sell 2,250 shares of common stock, valued at approximately $127,642.50, on 10/01/2026.
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
October 1, 2026 at 8:22 PM
🚨 $PCVX
Wassil Jim, a Officer, filed a notice of intent to sell 2,250 shares of common stock, valued at approximately $127,642.50, on 10/01/2026.
Wassil Jim, a Officer, filed a notice of intent to sell 2,250 shares of common stock, valued at approximately $127,642.50, on 10/01/2026.
$PCVX soars on positive Phase 3 VAX-31 data—met safety & efficacy endpoints, showed superiority on key serotypes. 2 missed non-inferiority vs PCV21 but still passed standard threshold.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 10/05/26
export-download.canva.com
October 5, 2026 at 12:40 PM
$PCVX soars on positive Phase 3 VAX-31 data—met safety & efficacy endpoints, showed superiority on key serotypes. 2 missed non-inferiority vs PCV21 but still passed standard threshold.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
12 best-performing US stocks October 5, 2026
1. #$PTC +33.49%
2. #$XP +30.93%
3. #$PCVX +30.70%
4. #$PICS +27.83%
5. #$AGBK +23.44%
6. #$RXO +22.54%
7. #$PAGS +21.40%
8. #$DNA +21.30%
9. #$STNE +20.84%
10. #$NVAX +20.08%
11. #$INTR +19.71%
12. #$BBD +18.75%
1. #$PTC +33.49%
2. #$XP +30.93%
3. #$PCVX +30.70%
4. #$PICS +27.83%
5. #$AGBK +23.44%
6. #$RXO +22.54%
7. #$PAGS +21.40%
8. #$DNA +21.30%
9. #$STNE +20.84%
10. #$NVAX +20.08%
11. #$INTR +19.71%
12. #$BBD +18.75%
October 6, 2026 at 1:34 AM
#$PCVX is up more than 50% premarket after VAX-31 met all prespecified primary endpoints in Phase 3.
Biotech headlines can look binary even when the trade isn't.
The 8:00 ET call matters because traders now have to price the details, not just the headline.
Biotech headlines can look binary even when the trade isn't.
The 8:00 ET call matters because traders now have to price the details, not just the headline.
October 5, 2026 at 11:55 AM
#$PCVX is up more than 50% premarket after VAX-31 met all prespecified primary endpoints in Phase 3.
Biotech headlines can look binary even when the trade isn't.
The 8:00 ET call matters because traders now have to price the details, not just the headline.
Biotech headlines can look binary even when the trade isn't.
The 8:00 ET call matters because traders now have to price the details, not just the headline.
📈 PCVX (Vaxcyte) +16.9% since we peeled back the filing
Filed: Oct 5, 2026 | 06:00 ET | Now: Oct 5, 2026 | 06:22 ET
At filing: $72.80 to Now: $85.08
Score: 9/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
Filed: Oct 5, 2026 | 06:00 ET | Now: Oct 5, 2026 | 06:22 ET
At filing: $72.80 to Now: $85.08
Score: 9/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
October 5, 2026 at 10:29 AM
📈 PCVX (Vaxcyte) +16.9% since we peeled back the filing
Filed: Oct 5, 2026 | 06:00 ET | Now: Oct 5, 2026 | 06:22 ET
At filing: $72.80 to Now: $85.08
Score: 9/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
Filed: Oct 5, 2026 | 06:00 ET | Now: Oct 5, 2026 | 06:22 ET
At filing: $72.80 to Now: $85.08
Score: 9/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
Vaxcyte ($PCVX) anunció que su vacuna antineumocócica 31-valente, VAX-31, cumplió los objetivos primarios en un ensayo fase 3 pivotal en adultos. Logró no inferioridad en 32 comparaciones de serotipos, con seguridad similar a PCV20/PCV21. Se esperan datos de los ensayos OPUS-2/3 en el primer[...]
October 5, 2026 at 11:20 AM
Vaxcyte ($PCVX) anunció que su vacuna antineumocócica 31-valente, VAX-31, cumplió los objetivos primarios en un ensayo fase 3 pivotal en adultos. Logró no inferioridad en 32 comparaciones de serotipos, con seguridad similar a PCV20/PCV21. Se esperan datos de los ensayos OPUS-2/3 en el primer[...]
Premarket Oct 5: two tapes. #$PTC +36% on Schneider's $205 cash buyout. #$RXO +21% on C.H. Robinson's $30.25 deal. #$PCVX +57% on a Phase 3 win. The casino: #$SAIQ +228% de-SPAC, #$SDEV +46% parabolic, #$PSKY +99% on split artifact. Buy the verified. Rent the casino. [NOT FINANCIAL ADVICE, DYOR!]
October 5, 2026 at 12:19 PM
Oct 5 open: #$PCVX +46% at $82.68 — VAX-31 Phase 3 swept every endpoint, Jefferies calls it 'blue-sky,' Mizuho $90–$100. But: opened $87.21, faded to $82.68. Serotypes 3/12F missed strict NI vs PCV21. BLA not until H1 2028. $12.35B, no revenue. Clean data, fading open. [NOT FINANCIAL ADVICE, DYOR!]
October 5, 2026 at 2:04 PM
Oct 5 open: #$PCVX +46% at $82.68 — VAX-31 Phase 3 swept every endpoint, Jefferies calls it 'blue-sky,' Mizuho $90–$100. But: opened $87.21, faded to $82.68. Serotypes 3/12F missed strict NI vs PCV21. BLA not until H1 2028. $12.35B, no revenue. Clean data, fading open. [NOT FINANCIAL ADVICE, DYOR!]
September 3, 2024 at 6:45 PM
September 3, 2024 at 3:35 PM